Study #2019-0012
BTK inhibitor zanubrutinib (BGB-3111) in combination with rituximab for previously untreated patients with Chronic Lymphocytic Leukemia (CLL)
MD Anderson Study Status
Enrolling
Treatment Agent
Rituximab, Zanubrutinib
Description
This phase II trial studies how well zanubrutinib and rituximab work in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma for which the patient has not received treatment in the past (previously untreated). Zanubrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. The study is being done to find out if zanubrutinib combined with rituximab can help control previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Study phase:
Phase II
Physician name:
Jan Burger
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.